Infrastructure at Scale: A Conversation with Germfree’s New CEO
May 26, 2026
We speak with Carol Houts about advanced therapy manufacturing, modular cleanrooms, and the challenge of scaling GMP infrastructure
7 min read
False
Advertisement
Facilities & Equipment
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
Interphex Insider: The Future-Ready Biomanufacturing Facility
May 15, 2026
Meg Carr reflects on the key themes from this year’s show – from contamination control and AI to flexible facility design
3 min read
A Modular Route to RNA Delivery
March 11, 2026
A supramolecular delivery platform forms self-assembling nanoparticles for RNA therapeutics
1 min read
Innovation Awards 2025: Vote for Your Winner
March 11, 2026
Help us choose the most impactful drug development and manufacturing technology of 2025
1 min read
Biopharma’s Survival Moment
March 2, 2026
Why the next decade will be defined by operational reinvention, not just scientific breakthroughs
5 min read
New Novartis Biomedical Research Facility Planned for San Diego
February 16, 2026
Part of a broader multibillion-dollar effort to expand R&D and manufacturing in the US
1 min read
Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC
By Achim Link
January 28, 2026
GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.
4 min read
Beating Biopharma Manufacturing Bottlenecks with Raman Spectroscopy
By Michelle Sestak
January 26, 2026
A look at the potential of Raman spectroscopy in biopharma – and what else lies on the horizon for this important technique
4 min read
Industry News
Facilities & Equipment
Future of Pharma
Interviews
Business & Trends
Technology & Manufacturing
Sustainability Is the New Survival Strategy
January 21, 2026
Green issues shouldn’t be treated as “woke.” Instead, they should be seen as pharma’s license to operate. Three industry experts discuss.
10 min read
